Fig. 4

Incorporation of ropivacaine into hydrogels increases MHC-I in vitro. A Schematic diagram of upregulation of MHC-I by ropivacaine. AP autophagosome, Rop ropivacaine, AL autolysosome. B Western blot results of LC3II and P62 in 4T1 cells treated with PF and PFR for 8 h, respectively. C, D Statistical results of western blots of LC3II and P62 (n = 4). E, F The mean fluorescence intensity (MFI) of MHC-I in 4T1 cells treated with PF and PFR for 8 h was detected by flow cytometry (n = 4). G MHC-I immunofluorescent staining. Scale bar = 20 μm. H Western blot results of LC3II and P62 in 4T1 cells treated with PFC and PFCR for 8 h, respectively. I, J Statistical results of western blots of LC3II and P62 (n = 4). K, L The mean fluorescence intensity (MFI) of MHC-I in 4T1 cells treated with PFC and PFCR for 8 h was detected by flow cytometry (n = 4). M MHC-I immunofluorescent staining. Scale bar = 20 μm. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. PF PF127 hydrogel, PFC cisplatin-loaded PF127 hydrogel, PFR ropivacaine-loaded PF127 hydrogel, PFCR cisplatin and ropivacaine-coloaded PF127 hydrogel